A clinical study by using Agnimukh Churna with Kapitthashtak Churna in Irritable Bowel Syndrome Disease.
Phase 4
Not yet recruiting
- Conditions
- Health Condition 1: K318- Other specified diseases of stomach and duodenum
- Registration Number
- CTRI/2023/04/051671
- Lead Sponsor
- Dr Ankita PAtil
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.Patients between 16-60 years of all genders.
2.Patients having lakshanas of grahani.
For Eg. Aruchi, Kshudhamadhya, Bahudravasaranam, Murhubaddham Murhudravam, Udardaha
Exclusion Criteria
Patients with major other diseases and who dont give consent.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To evaluate efficacy of Agnimukha churna on symptoms of Grahani as per subjective and objective assesment mentioned in the synopsisTimepoint: The improvement in the symptoms of Grahani with the help of Izumo scale will be graded at each follow up of 7th, 14th, 21st and 28th day.
- Secondary Outcome Measures
Name Time Method To compare mode of action of agnimukha churna and kapitthastak churna in the management of grahani. <br/ ><br>To check the safety or Adverse effects of the drugs.Timepoint: At every follow up i.e.on 7th,14th,21st and 28th day the comparative study will be done and safety will be assesed.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Agnimukh Churna and Kapitthashtak Churna's efficacy in IBS with gut microbiota modulation?
How does the combination of Agnimukh and Kapitthashtak Churna compare to standard IBS therapies like linaclotide or rifaximin in symptom management?
Are specific gut microbiota profiles or inflammatory biomarkers (e.g., IL-6, TNF-α) predictive of response to these Ayurvedic formulations in IBS-D or IBS-C subtypes?
What adverse events are associated with long-term use of Agnimukh Churna and Kapitthashtak Churna in Phase IV IBS trials, and how are they managed?
What other herbal compounds or Ayurvedic combinations show promise in targeting Grahani (IBS) through similar anti-inflammatory or gut motility pathways?